Scarica l'app Stockscreener
456.69
0.90%
-4.13
Dopo l'orario di chiusura:
454.13
-2.56
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$460.82
Aprire:
$457.3
Volume 24 ore:
1.17M
Relative Volume:
0.83
Capitalizzazione di mercato:
$116.01B
Reddito:
$12.07B
Utile/perdita netta:
$3.95B
Rapporto P/E:
29.78
EPS:
15.3349
Flusso di cassa netto:
$3.19B
1 W Prestazione:
-8.08%
1M Prestazione:
-4.44%
6M Prestazione:
+15.29%
1 anno Prestazione:
-5.98%
Intervallo 1D:
$450.67
$460.00
Intervallo di 1 settimana:
$450.67
$498.02
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex presents new Phase IV data on Journavx - The Pharma Letter
Quantbot Technologies LP Takes $1.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Dimensional Fund Advisors LP Purchases 187,359 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex to Participate in Upcoming March Investor Conferences - Business Wire
Vertex Pharmaceuticals to Present Data on JOURNAVX® for Pain Management After Aesthetic and Reconstructive Surgeries - geneonline.com
Did Vertex’s (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative? - Yahoo Finance
Vertex Pharmaceuticals Incorporated Presents New Data on JOURNAVX for Effective Pain Management Following Aesthetic and Reconstructive Procedures - marketscreener.com
Vertex Pharmaceuticals (VRTX) Reports Positive Phase 4 Study Res - GuruFocus
Non-opioid pain drug helps plastic surgery patients skip opioids - Stock Titan
2 Biotech Giants to Buy in 2026 - AOL.com
South Dakota Investment Council Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2 Biotech Giants to Buy in 2026 - The Motley Fool
CI Investments Inc. Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Hits Day High with Strong 3.48% Intraday Surge - Markets Mojo
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Is Vertex Pharmaceuticals (VRTX) Still Attractively Priced After Its Multi Year Share Price Run? - simplywall.st
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
Director files Form 144 to sell shares (NASDAQ: VRTX) - Stock Titan
Teachers Retirement System of Kentucky Reduces Vertex Pharmaceuticals Stake - National Today
Teachers Retirement System of The State of Kentucky Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
William Blair Investment Management LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Zacks Analyst Blog Highlights Broadcom, AT&T, Vertex and InterGroup - Zacks Investment Research
Top Research Reports for Broadcom, AT&T & Vertex Pharmaceuticals - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Executive Sells Shares - TradingView
Vertex (VRTX) CMO Carmen Bozic executes Rule 10b5-1 sale of 2,329 shares - Stock Titan
Vertex at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
Vertex at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com India
Vertex Pharma Stock: Why Wall Street Is Quietly Buying the Dip - AD HOC NEWS
Rafferty Asset Management Boosts Vertex Pharmaceuticals Stake - National Today
Victory Capital Management Inc. Buys 92,402 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wealthedge Investment Advisors Invests $965K in Vertex Pharmaceuticals - National Today
VRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
American Century Companies Reduces Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals Stock Holdings Reduced by US Bancorp - National Today
BMO Maintains Outperform on VRTX, Vertex Pharmaceuticals Incorporated Mar 2026 - Meyka
Vertex Pharmaceuticals (VRTX) Valuation Check After Q4 Beat And Growing Confidence In Povetacicept - simplywall.st
Joy Liu reports multiple share sales for VRTX (NASDAQ: VRTX) in Form 144 - Stock Titan
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Vertex (VRTX) SVP & Chief Accounting Officer sells 357 shares in open-market trade - Stock Titan
Vertex Gets Rating Upgrade, Earnings Rose Every Quarter This Past Year - Investor's Business Daily
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
111 Capital Invests $1.71 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Stock Holdings Lessened by US Bancorp DE - MarketBeat
Huntington National Bank Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
American Century Companies Inc. Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - simplywall.st
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vertex Pharmaceuticals Inc Azioni (VRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Liu Joy | EVP and Chief Legal Officer |
Mar 02 '26 |
Sale |
495.96 |
892 |
442,396 |
22,811 |
0.66%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):